Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced breast cancer with positive BRCA1 or BRCA2 status~* Failed at least one prior chemotherapy~* In investigators opinion, no curative standard therapy exists~* Measurable disease~Exclusion Criteria:~* Brain metastases~* Less than 28 days since last treatment used to treat the disease~* Considered a poor medical risk due to a serious uncontrolled disorder

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Olaparib 100 mg (Type: EXPERIMENTAL): Participants will receive two 50 mg capsules in the morning and two 50 mg capsules in the evening in 28-days cycle until confirmed disease progression, continuous treatment interruption, unacceptable toxicity or any other discontinuation criterion is met.
- Olaparib 400 mg (Type: EXPERIMENTAL): Participants will receive eight 50 mg capsules in the morning and eight 50 mg capsules in the evening in 28-days cycle until confirmed disease progression, continuous treatment interruption, unacceptable toxicity or any other discontinuation criterion is met.

Based on this trial design, predict the completion outcome and termination type (if applicable).